| Time (hrs) |
Pure drug suspension (ng/ml) |
Marketed Formulation(ng/ml) |
SNEDDS (ng/ml) |
| 0.25 |
19.15 ± 0.81 |
30.27 ± 1.21** |
48.25 ± 1.90**## |
| 0.5 |
25.20 ± 0.98 |
40.14 ± 1.75** |
69.15 ± 2.31***## |
| 0.75 |
34.89 ± 1.09 |
48.80 ± 1.92** |
78.13 ± 2.96***## |
| 1 |
53.6 ± 1.33 |
57.14 ± 1.98 |
80.25 ± 2.34**## |
| 2 |
56.42 ± 1.89 |
60.65 ± 2.13 |
76.47 ± 2.28**## |
| 4 |
40.55 ± 1.33 |
57.85 ± 1.94** |
69.75 ± 1.99**# |
| 6 |
35.46 ± 1.16 |
48.90 ± 1.89** |
60.43 ± 1.94** |
| 8 |
30.16 ± 0.98 |
40.38 ± 1.71* |
50.97 ± 1.78** |
| 12 |
24.39 ± 0.95 |
29.79 ± 1.54** |
32.18 ± 1.49** |
Values are expressed as mean ± S.D; n=2
*P<0.05; **P<0.01;***P<0.001 when compared with pure drug
#P<0.05; ##P<0.01 when compared with conventional formulation
One way ANOVA followed by TUKEY-KRAMERS multiple comparision tests. |
